Objective To investigate the effects of histone deacetylase inhibitor pabisterostat (LBH589) in combination with oxaliplatin (OXA) on human gallbladder cancer cell lines and the regulation of chemotherapy sensitivity. Methods:The effects of LBH589 and OXA alone and in combination on the proliferation of human gallbladder cancer cell lines GBC-SD and NOZ cells were examined by CCK-8 assay and plate cloning assay; the effects of LBH589 and OXA alone and in combination on the induction of cell cycle and apoptosis were determined by flow cytometry. Results:The results of CCK8 assay showed that the proliferation ability of LBH589 group and LBH589+OXA group of GBC-SD and NOZ cells were significantly decreased compared with the control group (P＜0.05); the results of plate cloning assay showed that the proliferation ability of OXA group, LBH589 group and LBH589+OXA group of GBCSD and NOZ cells were significantly decreased compared with the control group (P＜0.05); the results of plate cloning assay showed that the proliferation The cell cycle results showed that the S phase was significantly higher in the LBH589 and LBH589+OXA groups of GBC-SD and NOZ cells compared with the control group (P＜0.001); the apoptosis results showed that the apoptosis rate was significantly higher in the LBH589 and LBH589+OXA groups of GBC-SD and NOZ cells compared with the control group (P＜0.001). were significantly higher (P＜0.05). Conclusion:HDCAIs can inhibit the proliferation and cycle of GBC-SD and NOZ cells, promote apoptosis, and increase the sensitivity of GBC-SD and NOZ cells to OXA.
万方数据